Regent Pacific Group Limited, an investment holding company, holds investments in the healthcare and life sciences companies in China, Europe, Hong Kong, and Taiwan. It operates in two segments, Biopharma and Corporate Investment. The company engages in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders. It focuses on the commercialization of Fortacin, a topical prescription treatment for premature ejaculation. The company also invests in listed and unlisted corporate entities. In addition, it provides management, mill expansion, metallurgical, and corporate finance services. Further, the company focuses on zinc/copper projects in the Pilbara region of Western Australia. Regent Pacific Group Limited was founded in 1991 and is headquartered in Central, Hong Kong.